Silibinin improves nonalcoholic fatty liver by regulating the expression of miR‑122: An <em>in vitro</em> and <em>in vivo</em> study

Yang,Liying; Liu,Qianqian; Zhang,He; Wang,Yichao; Li,Yang; Chen,Shuchun; Song,Guangyao; Ren,Luping

doi:10.3892/mmr.2021.11974

Silibinin improves nonalcoholic fatty liver by regulating the expression of miR‑122: An in vitro and in vivo study

Authors:
- Liying Yang
- Qianqian Liu
- He Zhang
- Yichao Wang
- Yang Li
- Shuchun Chen
- Guangyao Song
- Luping Ren
View Affiliations

Affiliations: Endocrinology Department, Hebei General Hospital, Shijiazhuang, Hebei 050000, P.R. China
Published online on: March 8, 2021 https://doi.org/10.3892/mmr.2021.11974
Article Number: 335
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Silibinin is a flavonoid that improves fatty liver and insulin resistance. To elucidate the effect of silibinin on lipid deposition and the potential molecular mechanism, the present study conducted in vivo and in vitro experiments. In the in vivo experiments, mice were randomly divided into control, high‑fat and silibinin groups, while HepG2 cells were randomly divided into control, palmitic acid intervention and silibinin intervention groups. The mRNA, protein and miR‑122 expression associated with hepatic lipid metabolism were detected in each group. The results demonstrated that silibinin reduced the triglyceride content, miR‑122 expression and the mRNA and protein expressions of fatty acid synthase (FAS) and acetyl‑CoA carboxylase (ACC). Silibinin increased the mRNA and protein expression of carnitine palmitoyl transferase 1A (CPT1A). In the present study, HepG2 cells cultured with palmitate were treated with silibinin following overexpression of micro RNA (miR) 122. The results demonstrated that the mRNA and protein expression of FAS and ACC was increased, while that of CPT1A was decreased. Therefore, it could be deduced that silibinin improved lipid metabolism by reducing the expression of miR‑122 and inhibiting the expression of miR‑122 may be a new therapeutic target to improve fatty liver disease.

View Figures

View References

1	Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association; National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver and Metabolism, Chinese Society of Endocrinology, Chinese Medical Association, . Expert recommendations on standardized diagnosis and treatment for fatty liver disease in China (2019 revised edition). Zhonghua Gan Zang Bing Za Zhi. 27:748–753. 2019.(In Chinese). PubMed/NCBI
2	Yu Y, Cai J, She Z and Li H: Insights into the epidemiology, pathogenesis, and therapeutics of nonalcoholic fatty liver diseases. Adv Sci (Weinh). 6:18015852018. View Article : Google Scholar : PubMed/NCBI
3	Liu XL, Cao HX and Fan JG: MicroRNAs as biomarkers and regulators of nonalcoholic fatty liver disease. J Dig Dis. 17:708–715. 2016. View Article : Google Scholar : PubMed/NCBI
4	Miyaaki H, Ichikawa T, Kamo Y, Taura N, Honda T, Shibata H, Milazzo M, Fornari F, Gramantieri L, Bolondi L and Nakao K: Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int. 34:e302–307. 2014. View Article : Google Scholar : PubMed/NCBI
5	Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, Osakabe K, Sugimoto K, Ohashi K, Teradaira R, Inoue T, et al: Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta. 424:99–103. 2013. View Article : Google Scholar : PubMed/NCBI
6	Chai C, Rivkin M, Berkovits L, Simerzin A, Zorde-Khvalevsky E, Rosenberg N, Klein S, Yaish D, Durst R, Shpitzen S, et al: Metabolic circuit involving free fatty acids, microRNA 122, and triglyceride synthesis in liver and muscle tissues. Gastroenterology. 153:1404–1415. 2017. View Article : Google Scholar : PubMed/NCBI
7	Yamada H, Ohashi K, Suzuki K, Munetsuna E, Ando Y, Yamazaki M, Ishikawa H, Ichino N, Teradaira R and Hashimoto S: Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease. Clin Chim Acta. 446:267–271. 2015. View Article : Google Scholar : PubMed/NCBI
8	Singh S, Osna NA and Kharbanda KK: Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World J Gastroenterol. 23:6549–6570. 2017. View Article : Google Scholar : PubMed/NCBI
9	Salomone F, Godos J and Zelber-Sagi S: Natural antioxidants for non-alcoholic fatty liver disease: Molecular targets and clinical perspectives. Liver Int. 36:5–20. 2016. View Article : Google Scholar : PubMed/NCBI
10	Yao J, Zhi M, Gao X, Hu P, Li C and Yang X: Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver. Braz J Med Biol Res. 46:270–277. 2013. View Article : Google Scholar : PubMed/NCBI
11	Nair A, Morsy MA and Jacob S: Dose translation between laboratory animals and human in preclinical and clinical phases of drug development. Drug Dev Res. 79:373–382. 2018. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta DeltaC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Tilg H and Moschen AR: Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology. 52:1836–1846. 2010. View Article : Google Scholar : PubMed/NCBI
14	Lindenmeyer CC and McCullough AJ: The natural history of nonalcoholic fatty liver disease-an evolving view. Clin Liver Dis. 22:11–21. 2018. View Article : Google Scholar : PubMed/NCBI
15	Bouderba S, Sanchez-Martin C, Villanueva GR, Detaille D and Koceir EA: Beneficial effects of silibinin against the progression of metabolic syndrome, increased oxidative stress, and liver steatosis in Psammomys obesus, a relevant animal model of human obesity and diabetes. J Diabetes. 6:184–192. 2014. View Article : Google Scholar : PubMed/NCBI
16	Vecchione G, Grasselli E, Voci A, Baldini F, Grattagliano I, Wang DQ, Portincasa P and Vergani L: Silybin counteracts lipid excess and oxidative stress in cultured steatotic hepatic cells. World J Gastroenterol. 22:6016–6026. 2016. View Article : Google Scholar : PubMed/NCBI
17	Salamone F, Galvano F, Cappello F, Mangiameli A, Barbagallo I and Li Volti G: Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. Transl Res. 159:477–486. 2012. View Article : Google Scholar : PubMed/NCBI
18	Cui CX, Deng JN, Yan L, Liu YY, Fan JY, Mu HN, Sun HY, Wang YH and Han JY: Silibinin Capsules improves high fat diet-induced nonalcoholic fatty liver disease in hamsters through modifying hepatic de novo lipogenesis and fatty acid oxidation. J Ethnopharmacol. 208:24–35. 2017. View Article : Google Scholar : PubMed/NCBI
19	Salomone F, Barbagallo I, Godos J, Lembo V, Currenti W, Cinà D, Avola R, D'Orazio N, Morisco F, Galvano F and Li Volti G: Silibinin restores NAD⁺ levels and induces the SIRT1/AMPK pathway in non-alcoholic fatty liver. Nutrients. 9:10862017. View Article : Google Scholar
20	Zhang Y, Hai J, Cao M, Zhang Y, Pei S, Wang J and Zhang Q: Silibinin ameliorates steatosis and insulin resistance during non-alcoholic fatty liver disease development partly through targeting IRS-1/PI3K/Akt pathway. Int Immunopharmacol. 17:714–720. 2013. View Article : Google Scholar : PubMed/NCBI
21	Feng YY, Xu XQ, Ji CB, Shi CM, Guo XR and Fu JF: Aberrant hepatic microRNA expression in nonalcoholic fatty liver disease. Cell Physiol Biochem. 34:1983–1997. 2014. View Article : Google Scholar : PubMed/NCBI
22	Calo N, Ramadori P, Sobolewski C, Romero Y, Maeder C, Fournier M, Rantakari P, Zhang FP, Poutanen M, Dufour JF, et al: Stress-activated miR-21/miR-21* in hepatocytes promotes lipid and glucose metabolic disorders associated with high-fat diet consumption. Gut. 65:1871–1881. 2016. View Article : Google Scholar : PubMed/NCBI
23	Liu CH, Ampuero J, Gil-Gomez A, Montero-Vallejo R, Rojas A, Muñoz-Hernández R, Gallego-Durán R and Romero-Gómez M: miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol. 69:1335–1348. 2018. View Article : Google Scholar : PubMed/NCBI
24	Su D, Zhang R, Hou F, Chi J, Huang F, Yan S, Liu L, Deng Y, Wei Z and Zhang M: Lychee pulp phenolics ameliorate hepatic lipid accumulation by reducing miR-33 and miR-122 expression in mice fed a high-fat diet. Food Funct. 8:808–815. 2017. View Article : Google Scholar : PubMed/NCBI
25	Naderi M, Pazouki A, Arefian E, Hashemi SM, Jamshidi-Adegani F, Gholamalamdari O, Soudi S, Azadmanesh K, Samiee SM, Merat S, et al: Two triacylglycerol pathway genes, CTDNEP1 and LPIN1, are down-regulated by hsa-miR-122-5p in hepatocytes. Arch Iran Med. 20:165–171. 2017.PubMed/NCBI
26	Khakinezhad Tehrani F, Ranji N, Kouhkan F and Hosseinzadeh S: Apoptosis induction and proliferation inhibition by silibinin encapsulated in nanoparticles in MIA PaCa-2 cancer cells and deregulation of some miRNAs. Iran J Basic Med Sci. 23:469–482. 2020.PubMed/NCBI
27	Zadeh MM, Motamed N, Ranji N, Majidi M and Falahi F: Silibinin-induced apoptosis and downregulation of microRNA-21 and microRNA-155 in MCF-7 human breast cancer cells. J Breast Cancer. 19:45–52. 2016. View Article : Google Scholar : PubMed/NCBI